Volunteer
GSK Logo
Gastroenterology Societyof KenyaAdvancing Digestive Health Care
Back to Presentations
Oncology

Premalignant and Malignant Lesions of Upper GI Tract

Early detection and management of upper gastrointestinal malignancies. Comprehensive screening, diagnosis, and treatment approaches.

GSK Clinical Team
2025
GSK Clinical Research

Download Presentation

Download PowerPoint FileOpen in New Tab

Overview

Upper gastrointestinal malignancies represent a significant health burden worldwide. Early detection of premalignant lesions and timely intervention are crucial for improving patient outcomes and survival rates.

Key Focus Areas:

  • Early detection and screening strategies
  • Classification of premalignant lesions
  • Diagnostic approaches and staging
  • Treatment modalities and outcomes
  • Surveillance and follow-up protocols

Anatomical Sites

Esophagus

  • Squamous Cell Carcinoma

    Most common in upper and middle esophagus

  • Adenocarcinoma

    Associated with Barrett's esophagus

  • Premalignant: Barrett's Esophagus

    Metaplastic change requiring surveillance

Stomach

  • Adenocarcinoma

    Most common gastric malignancy

  • Gastrointestinal Stromal Tumor (GIST)

    Mesenchymal tumor

  • Premalignant: Gastric Atrophy, Intestinal Metaplasia

    Chronic gastritis progression

Risk Factors

Modifiable Risk Factors

  • • Tobacco smoking
  • • Alcohol consumption
  • • Dietary factors (processed meats, nitrates)
  • • Obesity and metabolic syndrome
  • • Helicobacter pylori infection
  • • Gastroesophageal reflux disease (GERD)

Non-Modifiable Risk Factors

  • • Age (increased risk with advancing age)
  • • Male gender
  • • Family history of GI cancers
  • • Genetic predisposition
  • • Previous history of GI malignancies
  • • Certain genetic syndromes

Screening & Early Detection

Screening Strategies

High-Risk Populations

  • • Barrett's esophagus patients
  • • Chronic GERD symptoms
  • • Family history of esophageal cancer
  • • Previous head/neck cancer

Screening Methods

  • • Upper GI endoscopy
  • • Chromoendoscopy
  • • Narrow-band imaging (NBI)
  • • Confocal laser endomicroscopy

Early Detection Benefits

  • • Improved survival rates with early-stage detection
  • • Less invasive treatment options
  • • Better quality of life outcomes
  • • Reduced healthcare costs
  • • Opportunity for curative treatment

Diagnostic Approaches

Endoscopic Evaluation

  • • High-definition white light endoscopy
  • • Narrow-band imaging (NBI)
  • • Chromoendoscopy with dyes
  • • Confocal laser endomicroscopy
  • • Endoscopic ultrasound (EUS)
  • • Optical coherence tomography

Tissue Sampling

  • • Targeted biopsies
  • • Random biopsies (surveillance)
  • • Endoscopic mucosal resection (EMR)
  • • Endoscopic submucosal dissection (ESD)
  • • Brush cytology
  • • Liquid biopsy techniques

Staging & Classification

TNM Staging System

T (Tumor)

Depth of tumor invasion

N (Nodes)

Lymph node involvement

M (Metastasis)

Distant metastasis

Staging Modalities

  • • Endoscopic ultrasound (EUS)
  • • CT scan with contrast
  • • PET-CT scan
  • • MRI imaging
  • • Laparoscopic staging

Histological Classification

  • • Adenocarcinoma
  • • Squamous cell carcinoma
  • • Neuroendocrine tumors
  • • Gastrointestinal stromal tumors
  • • Lymphomas

Treatment Modalities

Endoscopic Treatment

Early-Stage Lesions

  • • Endoscopic mucosal resection (EMR)
  • • Endoscopic submucosal dissection (ESD)
  • • Radiofrequency ablation (RFA)
  • • Cryotherapy

Palliative Procedures

  • • Stent placement
  • • Laser therapy
  • • Photodynamic therapy
  • • Argon plasma coagulation

Surgical Options

  • • Esophagectomy
  • • Gastrectomy
  • • Lymph node dissection
  • • Minimally invasive approaches

Multimodal Therapy

  • • Neoadjuvant chemotherapy
  • • Adjuvant therapy
  • • Radiation therapy
  • • Targeted therapy
  • • Immunotherapy

Surveillance & Follow-up

Surveillance Protocols

  • Regular endoscopic surveillance for high-risk patients
  • Systematic biopsy protocols for Barrett's esophagus
  • Post-treatment surveillance schedules
  • Risk stratification for surveillance intervals
  • Quality metrics for surveillance programs

Follow-up Care

  • • Regular clinical assessments
  • • Imaging surveillance
  • • Nutritional support
  • • Quality of life monitoring

Outcome Measures

  • • Survival rates
  • • Disease-free survival
  • • Quality of life scores
  • • Treatment-related complications

Key Takeaways

Summary Points:

  • Early detection significantly improves patient outcomes
  • Risk stratification guides screening and surveillance protocols
  • Multidisciplinary approach is essential for optimal care
  • Endoscopic techniques offer minimally invasive treatment options
  • Regular surveillance is crucial for high-risk patients
  • Quality metrics ensure effective screening programs